• ColonSentry® is an advanced blood-based molecular diagnostic test that measures the expression of seven gene biomarkers for the early detection of colorectal cancer.
  • This 7‐gene, blood‐based biomarker panel can stratify subjects according to their current relative risk across a broad range in an average‐risk population.
  • ColonSentry requires no fasting, dietary restrictions, or special instructions
  • ColonSentry does not require patients to provide or handle any stool samples.
  • ColonSentry is simple & convenient and blood can be drawn at an exam before patients leave the office.

ColonSentry® Patient Selection Criteria

The American Cancer Society recommends that people at average risk of colorectal cancer start regular screening at age 45. ³

Patients may be candidate for the ColonSentry® Test if they are:

  • Age 45 or older and at average risk for Colorectal Cancer;
  • Are without symptoms such as bleeding, abdominal pain, or change in bowel habits;
  • Have not had a Colonoscopy or Stool-Based Screening Test.

³ American Cancer Society. Guideline for Colorectal Cancer Screening. Last revised May 30, 2018.

Download ColonSentry® Physician Brochure

Clinical Utility

How to Interpret the ColonSentry Results to
Guide Treatment

Recommendations are Clear & Easy to Understand

Harnessing the Power of Gene Expression for
Early Cancer Detection